Ritter Pharmaceuticals believes its Phase II-stage drug candidate RP-G28, its first-in-class treatment for lactose intolerance, has the potential to become the first FDA-approved drug for the condition.
Ritter: RP-G28 has could become first FDA-approved lactose intolerance drug
Ritter Pharmaceuticals believes its Phase II-stage drug candidate RP-G28, its first-in-class treatment for lactose intolerance, has the potential to become the first FDA-approved drug for the condition.
More from Neurological
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
The FOCUS study met its primary and key secondary endpoints, but lack of statistical significance on the higher dose and a crowded market raised questions.
More from Therapeutic Category
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.